



Recommendation Report SCT-5

A Quality Initiative of the
Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO)

Extra-corporeal Photopheresis in the Management of Graft-Versus-Host Disease in Patients who Have Received Allogeneic Blood or Bone Marrow Transplants: Recommendations

C. Bredeson, R.B. Rumble, N.P. Varela, J. Kuruvilla, C.T. Kouroukis, and the Stem Cell Transplant Steering Committee

Report Date: August 29, 2013

An assessment conducted in February 2023 deferred review of Recommendation Report SCT-5. This means that the document remains current until it is assessed again next year. The PEBC has a formal and standardized process to ensure the currency of each document ([PEBC Assessment & Review Protocol](#))

Recommendation Report SCT-5 is comprised of 2 sections. You can access the summary and full report here:

<https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/966>

Section 1:	Recommendations
Section 2:	Evidentiary Base

For information about the PEBC and the most current version of all reports, please visit the CCO website at <http://www.cancercare.on.ca/> or contact the PEBC office at:
Phone: 905-527-4322 ext. 42822 Fax: 905-526-6775 E-mail: ccopgi@mcmaster.ca

PEBC Report Citation (Vancouver Style): Bredeson C, Rumble RB, Varela NP, Kuruvilla J, Kouroukis CT; Stem Cell Transplant Steering Committee. Extra-corporeal photopheresis in the management of graft-versus-host disease in patients who have received allogeneic blood or bone marrow transplants: recommendations. Toronto (ON): Cancer Care Ontario; 2013 Aug 29. Program in Evidence-Based Care Recommendation Report No.: SCT-5.

Journal Citation (Vancouver Style): Bredeson C, Rumble RB, Varela NP, Kuruvilla J, Kouroukis CT; Stem Cell Transplant Steering Committee. Extracorporeal photopheresis in the management of graft-versus-host disease. *Curr Oncol.* 2014;21(2):e310-25.

Recommendation Report SCT-5

Recommendation Report SCT-5: Section 1

A Quality Initiative of the
Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO)

Extra-corporeal Photopheresis in the Management of Graft-Versus-Host Disease in Patients who Have Received Allogeneic Blood or Bone Marrow Transplants: Recommendations

C. Bredeson, R.B. Rumble, N.P. Varela, J. Kuruvilla, C.T. Kouroukis, and the Stem Cell Transplant Steering Committee

Report Date: August 29, 2013

RESEARCH QUESTION

Is there a benefit associated with the use of extra-corporeal photopheresis (ECP) compared with other treatment options for patients who have received an allogeneic transplant and are experiencing graft-versus-host disease (GVHD) if response rate, survival, or improvement in symptoms are the outcomes of interest?

TARGET POPULATION

Adult and paediatric patients who have received an allogeneic transplant and are experiencing graft-versus-host disease.

RECOMMENDATIONS AND JUSTIFICATION

Extra-corporeal Photopheresis (ECP) in the Management of Graft-Versus-Host Disease (GVHD)

- | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <ul style="list-style-type: none">ECP is an acceptable therapy for the treatment of steroid-dependent / refractory acute GVHD in adult and paediatric patients |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Justification:

Three non-comparative studies in adult patients [one prospective single cohort (8) and two case series (1,2)], and six studies in paediatric patients [one clinical trial (3), one prospective cohort (4), and four case series (5-8)] reported response rates in favour of the ECP ranging from 32% to 100%. Only one of the paediatric studies reported comparable response rates between patients who received ECP and patients who remained on conventional treatment (6).

In the opinion of the Expert Panel, although the quality of the data for steroid refractory aGVHD is limited, patients with primarily refractory skin GVHD should be considered for ECP treatment.

Recommendation Report SCT-5

- ECP is an effective therapy for the treatment of steroid-dependent / refractory chronic GVHD in adult and paediatric patients

Justification:

This recommendation is supported by the evidence obtained from two studies [an RCT (9), and a crossover RCT (10)], because in both studies, significant increase in response rates favour the ECP over conventional corticosteroid treatment. Five additional comparative studies (3,4,11-13) and six non-comparative studies (2,5,7,8,14,15) reported response rates ranging from 50% to 80%.

QUALIFYING STATEMENTS

- ECP is currently a covered therapy in Ontario for patients with steroid refractory GVHD who meet certain eligibility criteria

FUTURE RESEARCH

- Patients should be encouraged to participate in National and International trials evaluating ECP as available
- Ontario transplant centres should develop a study evaluating the effectiveness of ECP

RELATED PROGRAM IN EVIDENCE-BASED CARE GUIDELINES

Stem Cell Transplantation in Adults, K. Imrie, R.B. Rumble, M. Crump, the Advisory Panel on Bone Marrow and Stem Cell Transplantation, and the Hematology Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care [Report Date: January 30, 2009].

Available at: <https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/951>

Funding

The PEBC is a provincial initiative of Cancer Care Ontario supported by the Ontario Ministry of Health and Long-Term Care. All work produced by the PEBC is editorially independent from the Ontario Ministry of Health and Long-Term Care.

Updating

All PEBC documents are maintained and updated as described in the PEBC Document Assessment and Review Protocol.

Copyright

This report is copyrighted by Cancer Care Ontario; the report and the illustrations herein may not be reproduced without the express written permission of Cancer Care Ontario. Cancer Care Ontario reserves the right at any time, and at its sole discretion, to change or revoke this authorization.

Disclaimer

Care has been taken in the preparation of the information contained in this report. Nonetheless, any person seeking to apply or consult the report is expected to use independent medical judgment in the context of individual clinical circumstances or seek out the supervision of a qualified clinician. Cancer Care Ontario makes no representation or guarantees of any kind whatsoever regarding the report content or use or application and disclaims any responsibility for its application or use in any way.

Contact Information

For information about the PEBC and the most current version of all reports, please visit the CCO website at <http://www.cancercare.on.ca/> or contact the PEBC office at: Phone: 905-527-4322 ext. 42822 Fax: 905 526-6775 E-mail: ccopgi@mcmaster.ca